Wills Hughes-Wilson is Head of Patient Access & Commercial Planning at Mereo Biopharma and a member of the company’s executive leadership team. She joined Mereo in February 2018 with responsibility for leading and optimising the company’s patient access and commercialisation strategies.
Prior to joining Mereo, Hughes-Wilson was Chief Patient Access Officer and SVP Patient Access & External Affairs at Sobi, with executive accountability for Sobi’s go-to-market approach across a broad orphan drug portfolio. This included leading the global pricing, reimbursement and access teams, notably for the company’s successful first-in-class haemophilia product launches; as well as the market-oriented development approach across the company’s early-stage clinical development portfolio.
Previous to that, she was Vice President Health & Market Access Policy at Genzyme.
Hughes-Wilson has been an active participant in the field of rare diseases and orphan drugs since the early 2000s, spanning membership of the EMA’s COMP Working Group with Interested Parties, the European Commission’s EU Committee of Experts on Rare Diseases (EUCERD) and, currently, the Steering Group of the European Mechanism of Coordinated Access (MoCA), a European payer-led multi-stakeholder forum seeking to address reimbursed availability of orphan drugs in Europe.
Hughes-Wilson is an honours graduate in Law.